EP Patent

EP4288427A1 — Gpr84 antagonists and uses thereof

Assigned to Liminal Biosciences Ltd · Expires 2023-12-13 · 2y expired

What this patent protects

The present invention provides compounds of formula (I), compositions thereof, and methods of using the same for the inhibition of GPR84, and the treatment of GPR84-mediated disorders.

USPTO Abstract

The present invention provides compounds of formula (I), compositions thereof, and methods of using the same for the inhibition of GPR84, and the treatment of GPR84-mediated disorders.

Drugs covered by this patent

Patent Metadata

Patent number
EP4288427A1
Jurisdiction
EP
Classification
—
Expires
2023-12-13
Drug substance claim
No
Drug product claim
No
Assignee
Liminal Biosciences Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.